Key result
SELFMAN-HF protocol evaluates if SCRinHF achieves 80% concordance with CFPI for predicting CHF readmissions on SGLT2i.
Why the study?
Congestive heart failure causes significant morbidity, mortality, and escalating costs, but challenges remain in standardising and implementing chronic disease self-management programmes.
Does the short-form SCRinHF tool provide concordant readmission risk prediction compared to the comprehensive CFPI tool in patients with HFrEF starting SGLT2 inhibitors?
Observational (n=40)
Single-blind
No
Does the short-form SCRinHF tool provide concordant readmission risk prediction compared to the comprehensive CFPI tool in patients with HFrEF starting SGLT2 inhibitors?
This study protocol outlines a prospective observational study to validate a short-form self-management and readmission risk prediction tool (SCRinHF) against an established comprehensive tool in patients with HFrEF starting SGLT2 inhibitors.
Validation protocol for SCRinHF in HFrEF on SGLT2 inhibitors leaves open short-form readmission prediction utility; prospective data needed before adoption.
Introduction Congestive heart failure (CHF) causes significant morbidity and mortality. It is an epidemic, and costs are escalating. CHF is a chronic disease whose trajectory includes stable phases, periods of decompensation, and finally palliation. Health services and medical therapies must match the various patient needs. Chronic disease self-management (CDSM) programmes that are patient-focused, identify problems and set actionable goals that appear as a logical, cost-friendly method to navigate patient journeys. There have been challenges in standardising and implementing CHF programmes. Methods and analysis SELFMAN-HF is a prospective, observational study to evaluate the feasibility and validity of the SCRinHF tool, a one-page self-management and readmission risk prediction tool for CHF, with an established, comprehensive CDSM tool. Eligible patients will have CHF with left ventricular ejection fraction <40% and commenced sodium glucose co-transporter-2 inhibitors (SGLT2-i) within 6 months of recruitment. The primary endpoint is the 80% concordance in readmission risk predicted by the SCRinHF tool. The study will recruit >40 patients and is expected to last 18 months. Ethics and dissemination This study has been approved by the St Vincent’s ethics committee (approval no. LRR 177/21). All participants will complete a written informed consent prior to enrolment in the study. The study results will be disseminated widely via local and international health conferences and peer-reviewed publications.
No takes yet. Share an insight, caveat, or question.
Iyngkaran et al. (2023) conducted an observational in Congestive heart failure (n=40). SCRinHF tool (short form) vs. Flinders Program of Chronic Condition Self-management Tool (CFPI) (long form) was evaluated on 80% concordance in readmission risk and MACE predicted by the SCRinHF tool compared to the CFPI tool. The SELFMAN-HF prospective observational study protocol aims to evaluate whether the short-form SCRinHF tool achieves 80% concordance with the long-form CFPI tool in predicting readmission risk for patients with congestive heart failure starting SGLT-2 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: